Adaptimmune company information, Employees & Contact Information

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp? ts2.tech

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds Newsfile

Adaptimmune's Groundbreaking Cell Therapy Assets Acquired by US WorldMeds in $85M Strategic Deal Stock Titan

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK Yahoo Finance

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? ts2.tech

Adaptimmune Reports Q1 Financial Results and Provides Business Update Stock Titan

FDA Approves Adaptimmune’s TCR T-cell Therapy Afami-cel for Synovial Sarcoma CGTLive®

(afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor Business Wire

Adaptimmune: Drug Approval Now Imminent? (NASDAQ:ADAP) Seeking Alpha

Roche, Adaptimmune part ways on cell therapy research BioPharma Dive

Adaptimmune Financial Alert: $152M Cash Left as Cell Therapy Sales Show Promise Stock Titan

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024 Yahoo Finance

Adaptimmune Announces Delisting from Nasdaq Newsfile

SPEARHEAD-1 Supports Potential TCR-T Approval for Synovial Sarcoma CGTLive®

Adaptimmune Reports Q3 2024 Financial and Business Updates Yahoo Finance

Adaptimmune Reports Q2 Financial Results and Provides Business Update Yahoo Finance

Oct 27 trading suspension — Adaptimmune to voluntarily delist ADSs from Nasdaq; Form 25 filing Oct 28, 2025 Stock Titan

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company Yahoo Finance

Adaptimmune Announces Changes to Board of Directors Yahoo Finance

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) Yahoo Finance

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024 Seeking Alpha

Adaptimmune Provides Q4 and Full Year 2024 Business Update Newsfile

FDA Accepts Adamptimmune’s BLA for Synovial Sarcoma TCR T-cell Therapy Afami-cel With Priority Review CGTLive®

Adaptimmune Reports Q1 Financial Results and Provides Business Update Newsfile

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) Newsfile

Interview with the CEO: Adaptimmune Therapeutics PLC (NASDAQ:ADAP) The Wall Street Transcript

FDA Clears Companion Diagnostic for Afami-Cel in Pretreated Metastatic Synovial Sarcoma OncLive

Adaptimmune Announces Clinical Responses across Five Solid GlobeNewswire

Adaptimmune and TCR² Therapeutics Announce Strategic GlobeNewswire

GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK GSK

FDA Grants Accelerated Approval to Afami-Cel for Advanced Synovial Sarcoma OncLive

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma OncLive

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback? ts2.tech

GSK and Adaptimmune expand strategic immunotherapy collaboration GSK

Women in STEM with Dr Jo Brewer Drug Target Review

Adaptimmune Faces Nasdaq Delisting Notice for Low Market Value MSN

Adaptimmune Growth Leads to Long-Term Expansion Plans in Philadelphia GlobeNewswire

ROTH Capital Partners to Host Inaugural Healthcare GlobeNewswire

T cell receptor binding affinity governs the functional profile of cancer‐specific CD8+ T cells Wiley Online Library

Engineered killer T cell recognizes HIV-1's lethal molecular disguises EurekAlert!